Adrenocortical Carcinoma Clinical Trials

12 recruiting

Adrenocortical Carcinoma Trials at a Glance

14 actively recruiting trials for adrenocortical carcinoma are listed on ClinicalTrialsFinder across 6 cities in 8 countries. The largest study group is Phase 2 with 7 trials, with the heaviest enrollment activity in New York, Würzburg, and Villejuif. Lead sponsors running adrenocortical carcinoma studies include University of Wuerzburg, Columbia University, and Azienda Socio Sanitaria Territoriale degli Spedali Civili di Brescia.

Browse adrenocortical carcinoma trials by phase

Treatments under study

About Adrenocortical Carcinoma Clinical Trials

Looking for clinical trials for Adrenocortical Carcinoma? There are currently 12 studies actively recruiting participants. Clinical trials offer access to new treatments before they are widely available, and every approved therapy in use today was first tested through a clinical trial.

Below you can browse trials, sign up for alerts when new Adrenocortical Carcinoma trials open, and view eligibility criteria for each study. Each listing includes the study phase, locations, and enrollment details.

Frequently Asked Questions

Common questions about Adrenocortical Carcinoma clinical trials

A clinical trial is a carefully designed research study that tests new medical treatments, drugs, devices, or approaches in human volunteers. Every approved medication and treatment available today was proven safe and effective through clinical trials.

All clinical trials are reviewed and approved by Institutional Review Boards (IRBs) — independent committees that evaluate patient safety. Trials follow strict protocols, and your health is monitored closely throughout. You can withdraw at any time.

Not necessarily. Many trials compare the new treatment against the current standard of care, meaning all participants receive active treatment. When placebos are used, they are typically combined with standard treatment, not given alone. The trial description will always specify the design.

Under the Affordable Care Act, most private insurers are required to cover routine patient care costs during a clinical trial. The sponsor typically covers the investigational treatment itself. Medicare also covers routine costs for qualifying trials.

Yes. Participation is completely voluntary. You can withdraw at any time, for any reason, without it affecting your access to standard medical care.

Each trial has specific eligibility criteria — including age, diagnosis, disease stage, prior treatments, and general health. Browse the trials listed above and check their eligibility sections. You can also contact the trial site directly to discuss your situation.

Showing 114 of 14 trials

Recruiting
Phase 1

Study of Preoperative Radiation Therapy in Participants With Resectable Recurrent Abdominal Adrenocortical Carcinoma

Adrenocortical Carcinoma (ACC)Carcinoma, AdrenocorticalCarcinoma, Adrenal Cortical+2 more
National Cancer Institute (NCI)32 enrolled1 locationNCT06487481
Recruiting

Familial Investigations of Childhood Cancer Predisposition

Hereditary Breast and Ovarian CancerHodgkin LymphomaAdrenocortical Carcinoma+30 more
St. Jude Children's Research Hospital1,500 enrolled1 locationNCT03050268
Recruiting
Phase 2

Study of Radiotherapy and Pembrolizumab in People With Adrenocortical Carcinoma

Adrenocortical CarcinomaACCMetastatic Adrenocortical Carcinoma
Memorial Sloan Kettering Cancer Center12 enrolled7 locationsNCT06066333
Recruiting
Phase 1

Gene Modified Immune Cells After Conditioning Regimen for the Treatment of Stage IIIC or IV Melanoma or Metastatic Solid Tumors

Breast CancerHead and Neck Squamous Cell CarcinomaMetastatic Malignant Solid Neoplasm+14 more
Anusha Kalbasi18 enrolled3 locationsNCT04119024
Recruiting
Phase 1

A Study of DS9051b in Participants With Advanced or Metastatic Adrenocortical Carcinoma and Metastatic Castration-resistant Prostate Cancer

Metastatic Castration-resistant Prostate CancerAdvanced or Metastatic Adrenocortical Carcinoma
Daiichi Sankyo40 enrolled6 locationsNCT07189403
Recruiting
Phase 2

Dostarlimab for Locally Advanced or Metastatic Cancer (Non-colorectal/Non-endometrial) With Tumor dMMR/MSI

Soft Tissue SarcomaPancreatic AdenocarcinomaAdrenocortical Carcinoma+2 more
UNICANCER120 enrolled22 locationsNCT06333314
Recruiting
Phase 2

Surgery and Heated Intraperitoneal Chemotherapy for Adrenocortical Carcinoma

Peritoneal CarcinomatosisAdrenocortical Carcinoma
Columbia University30 enrolled1 locationNCT03127774
Recruiting

Adrenal Tumors - Pathogenesis and Therapy

PheochromocytomaAdrenocortical CarcinomaCushing Syndrome+2 more
University of Wuerzburg500 enrolled1 locationNCT00669266
Recruiting

German Adrenocortical Carcinoma Registry

Adrenocortical Carcinoma
University of Wuerzburg1,000 enrolled1 locationNCT00453674
Recruiting
Phase 2

Phase II Study of PD-1 Antibody Combined With Radiotherapy in Recurrent or Metastatic Adrenal Cortical Carcinoma

Adrenocortical Carcinoma
Sun Yat-sen University18 enrolled1 locationNCT06587802
Recruiting
Phase 2

Pembrolizumab in the Treatment of Advanced, Progressive Adrenocortical Carcinoma.

Adrenocortical Carcinoma
Maria Sklodowska-Curie National Research Institute of Oncology24 enrolled4 locationsNCT05563467
Recruiting
Phase 2

Evaluation of the Efficacy of Addition of Progesterone to Standard Chemotherapy in Adrenocortical Carcinoma (ACC)

Adrenocortical Carcinoma
Azienda Socio Sanitaria Territoriale degli Spedali Civili di Brescia80 enrolled1 locationNCT05913427
Recruiting
Phase 2

Phase II Study for Combination of Camrelizumab and Apatinib in the Second-line Treatment of Recurrent or Metastatic Adrenocortical Carcinoma

Adrenocortical Carcinoma
West China Hospital21 enrolled1 locationNCT04318730
Recruiting

Surgical Treatment of Adrenal Diseases- Laparoscopic vs. Robotic-assisted Adrenalectomy

PheochromocytomaAdrenocortical CarcinomaCushing Syndrome+10 more
University Hospital Olomouc100 enrolled1 locationNCT06050057